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In 2005, the International Committee of Medical 
Journal Editors (ICMJE) initiated a policy requiring 
investigators to deposit information about trial design 
into an accepted clinical trials registry before the onset 
of patient enrolment.1 This policy aimed to ensure 
that information about the e�istence and design of 
clinically directive trials was publicly available, an 
ideal that leaders in evidence based medicine have 
advocated for decades.2 The policy precipitated much 
angst among research investigators and sponsors, 
who feared that registration would be burdensome 
and would stifle competition. Yet, the response to this 
policy has been overwhelming. The ICMJE prom-
ised to re-evaluate the policy two years after imple-
mentation. Here, we summarise that re-evaluation, 
specifically commenting on registries that meet the 
policy requirements, the types of studies that require 
registration, and the registration of trial results. As is 
always the case, the ICMJE establishes policy only 
for the 12 member journals (a detailed description of 
the ICMJE and its purpose is available at www.icmje.
org), but many other journals have adopted our initial 
trial registration recommendations, and we hope that 
they will also adopt the modifications discussed in 
this update.
The research community has embraced trial regis-
tration. Before the ICMJE policy, ClinicalTrials.gov, 
the largest trial registry at the time, contained 13 153 
trials; this number climbed to 22 714 one month 
after the policy came into effect.3 In April 2007, the 
registry contained over 40 000 trials, with more than 
200 new trial registrations occurring weekly (D Zarin, 
personal communication). The four other registries 
that meet the ICMJE criteria have also grown as 
scores of journals have adopted the ICMJE clinical 
trials registration policy. In response to burgeoning 
registration, many investigators, sponsors, and 
government agencies have asked the ICMJE to 
recognise their local registries as databases that 
meet the policy. Fortunately, the World Health 
Organization’s (WHO) International Clinical Tri-
als Registry Platform (ICTRP), which was nascent 
when the ICMJE began to require trial registration, 
has matured rapidly and provides options for those 
who desire a wider array of registries. The ICTRP has 
taken the first steps towards developing a network of 
primary and partner registers that meet WHO speci-
fied criteria.4 Primary registers are WHO selected 
registers managed by not-for-profit entities that will 
accept registrations for any interventional trials, delete 
duplicate entries from their own register, and provide 
data directly to WHO. Partner registers, which will be 
more numerous, will include registers that submit data 
to primary registers but limit their own register to trials 
So what is the most effective strategy to reduce 
harm from amphetamine-type substances? Although 
the manufacture and misuse of synthetic stimulants 
contribute greatly to morbidity and mortality in sub-
stance users worldwide, the global disease burden 
of this class of substances is much lower than that 
of tobacco, alcohol, and marijuana.6 9 10 Also, most 
people who use amphetamine-type substances take 
multiple substances.11
Even if the pattern of drug use is stable over time, 
drug markets are dynamic. Efforts to prevent the 
manufacture and use of amphetamine-type substances 
should, therefore, be integrated into a rational scheme 
to reduce overall substance use that is designed to 
tackle e�isting and emerging drug threats. Over- 
investing resources in the control of one drug, or one 
precursor, carries with it the risk of failing to appre-
ciate emerging threats. For instance, many people 
fear the “meth crisis,” but fewer seem aware of the 
recent warnings issued by the UN Office of Drugs 
and Crime about the resurgence of cocaine in Western 
Europe.12
Responses to this crisis should include limiting 
supply and distribution,13 educating the public about 
harms, screening for early use, and aggressively treat-
ing addiction in an integrated approach that tackles 
addiction in its many forms.
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in a restricted area (such as a specific disease, com-
pany, academic institution, or geographic region).
The ICMJE strongly supports WHO’s efforts, 
through the ICTRP, to develop a coordinated process 
for identifying, gathering, deduplicating, and search-
ing trials from registries around the world, thus even-
tually providing a one stop search portal for those 
seeking information about clinical trials. In addition 
to the five e�isting registries, the ICMJE will now also 
accept registration in any of the primary registers that 
participate in WHO ICTRP. Because it is crucial that 
trial registries are independent of for-profit interests, 
the ICMJE policy requires registration in a WHO pri-
mary register rather than solely in a partner register, 
since for-profit entities manage some partner regis-
ters. As previously, trial registration with missing or 
uninformative fields for the minimum data elements 
is inadequate.1
Initially, the ICMJE required registration of all clini-
cally directive trials, which it defined as “any research 
project that prospectively assigns human subjects to 
intervention or comparison groups to study the cause 
and effect relationship between a medical intervention 
and a health outcome.”1 In May 2005, the ICMJE 
clarified this definition to e�clude preliminary trials 
designed to study pharmacokinetics or major unknown 
to�icity (phase I trials).5 However, the ICMJE rec-
ognises the potential benefit of having information 
about preliminary trials in the public domain, because 
these studies can guide future research or signal safety 
concerns. Consequently, the ICMJE is e�panding the 
definition of the types of trials that must be registered 
to include these preliminary trials and adopts WHO’s 
definition of a clinical trial, “any research study that 
prospectively assigns human participants or groups of 
humans to one or more health-related interventions 
to evaluate the effects on health outcomes.”4 Health 
related interventions include any intervention used 
to modify a biomedical or health related outcome 
(for e�ample, drugs, surgical procedures, devices, 
behavioural treatments, dietary interventions, and 
process of care changes). Health outcomes include 
any biomedical or health related measures obtained 
in patients or participants, including pharmacokinetic 
measures and adverse events. As previously, purely 
observational studies (those in which the assignment 
of the medical intervention is not at the discretion 
of the investigator) will not require registration. The 
ICMJE member journals will start to implement the 
e�panded definition of clinically directive trials for 
all trials that begin enrollment on or after 1 July 2008. 
Those who are uncertain whether their trial meets the 
e�panded ICMJE definition should err on the side 
of registration if they wish to seek publication in an 
ICMJE journal.
Over the time during which registration of trial 
methods has become common practice, several forces 
have begun advocating for registration of trial results. 
We recognise that the climate for results registration 
will probably change dramatically and unpredictably 
over coming years. For the present, the ICMJE will 
not consider results posted in the same primary clini-
cal trials register in which the initial registration resides 
as previous publications if the results are presented in 
the form of a brief, structured (<500 words) abstract or 
table. The ICMJE favours a standard abstract format 
for results reporting, and the CONSORT (Consoli-
dated Standards for the Reporting of Trials) group’s 
forthcoming guidelines for abstracts related to trials 
may be one such option. The ICMJE believes that 
parties interested in results registration should con-
sider requiring the deposition of such an abstract in 
the registry 24 months after closure of data collection 
if results are not published in a peer reviewed venue 
by that time. The registered abstract should either cite 
any related full, peer reviewed publications or include 
a statement that indicates that the report has not yet 
been published in a peer reviewed journal. Research-
ers should be aware that editors may consider more 
detailed deposition of trial results in publicly available 
registries to be prior publication. When submitting 
a paper, authors should fully disclose to editors all 
posting in registries of results of the same or closely 
related work.
Three years ago, trial registration was the e�ception; 
now it is the rule. Registration facilitates the dissemi-
nation of information among clinicians, researchers, 
and patients, and it helps to assure trial participants 
that the information that accrues as a result of their 
altruism will become part of the public record. WHO’s 
global efforts towards comprehensive trial registration 
and the ICMJE’s requirements for registration aim to 
increase public trust in medical science.
1  Clinical trial registration: a statement from the International 
Committee of Medical Journal Editors. www.icmje.org/clin_trial.pdf.
2   Simes RJ. Publication bias: the case for an international registry of 
clinical trials. J Clin Oncol 1986;4:1529-41. 
3   Zarin DA, Tse T, Ide NC. Trial registration at ClinicalTrials.gov between         
May and October 2005. N Engl J Med 2005;353:2779-87. 
4  World Health Organization. International Clinical Trials Registry 
Platform. www.who.int/ictrp/about/details/en/index.html.
5   International Committee of Medical Journal Editors. Is this clinical 
trial fully registered? A statement from the International Committee of 
Medical Journal Editors. www.icmje.org/clin_trialup.htm.
1178	 	 	 BMJ | 9 June  2007 | VoluMe 334
Summary 
In addition to accepting registration in any of the five 
existing registries, the International Committee of 
Medical Journal Editors (ICMJE) will accept registration 
of clinical trials in any of the primary registers that 
participate in WHO’s International Clinical Trials Registry 
Platform (ICTRP). Registration in a partner register only is 
insufficient
The ICMJE will begin to implement the WHO definition 
of clinical trials for all trials that begin enrollment on or 
after 1 July 2008. This definition states that a clinical trial 
is “any research study that prospectively assigns human 
participants or groups of humans to one or more health-
related interventions to evaluate the effects on health 
outcomes”
The ICMJE will not consider results posted in the same 
clinical trials registry in which the primary registration 
resides to be a previous publication if the results are 
presented in the form of a brief, structured (<500 words) 
abstract or table.
•
•
•
